OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. The company's products include the OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and the OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies.
Additionally, the company offers Intercept drug testing systems, immunoassay tests and reagents, and the Q.E.D. saliva alcohol test. It also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva, as well as Colli-Pee collection devices for the volumetric collection of void urine samples.
In addition, the company offers microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and the OMNIgene GUT Dx collection device for the collection of human fecal samples and the stabilization of DNA from the bacterial community.
Furthermore, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets.
OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in...
